Cristina Gasparetto, MD, Oncology, Durham, NC, Duke University Hospital

CristinaGasparettoMD

Oncology Durham, NC

Associate Professor, Medicine, Duke University School of Medicine

Dr. Gasparetto is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gasparetto's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology/Oncology, 1996 - 1999
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1993 - 1996
  • Sapienza University of Rome
    Sapienza University of RomeClass of 1986

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1997 - 2022

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
    Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
    Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM) 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to Be Presented at the American Society of Hematology 2020 Annual Meeting
    Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to Be Presented at the American Society of Hematology 2020 Annual MeetingNovember 4th, 2020
  • OncLive® Presents State of the Science Summit™ on Hematologic Malignancies
    OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
  • Expert Highlights Early Promise of Selinexor in Myeloma
    Expert Highlights Early Promise of Selinexor in MyelomaFebruary 8th, 2018

Hospital Affiliations